http://orcid.org/0000-0003-0174-1065
References
- Ghaffar F, Friedland IR, McCracken GH-J. Dynamics of nasopharyngeal colonization by Streptococcus pneumoniae. Pediatr Infect Dis J. 1999;18(7):638–646.
- Lynch JP 3rd, Zhanel GG. Streptococcus pneumoniae: epidemiology, risk factors, and strategies for prevention. Semin Respir Crit Care Med. 2009;30(2):189–209. doi: 10.1055/s-0029-1202938.
- World Health Organization. Immunization, vaccines and biologicals - pneumococcal disease. 2011 [ accessed 2018 Jan 4]. http://www.who.int/immunization/topics/pneumococcal_disease/en/.
- Centers for Disease Control and Prevention (CDC). Global Immunization - new and underused vaccines. Pneumococcus. 2017 [ accessed 2017 Jul 22]. https://www.cdc.gov/globalhealth/immunization/sis/vacs_detail.htm#Pneumo.
- World Health Organization. Pneumococcal vaccines WHO position paper. 2012 [ accessed]. http://www.who.int/wer/2012/wer8714.pdf.
- Weinberger DM, Trzcinski K, Lu YJ, Bogaert D, Brandes A, Galagan J, Anderson PW, Malley R, Lipsitch M. Pneumococcal capsular polysaccharide structure predicts serotype prevalence. PLoS Pathog. 2009;5(6):e1000476. doi: 10.1371/journal.ppat.1000706.
- Choi EH, Kim KH, Kim YJ, Kim JH, Park SE, Lee HJ, Eun BW, Jo DS, Choi KM, Hong YJ. Recommendation for use of the newly introduced pneumococcal protein conjugate vaccines in Korea. Korean J Pediatr. 2011;54(4):146–151. doi: 10.3345/kjp.2011.54.4.146.
- European Medicines Agency 2017. Synflorix summary of product characteristics. 2017 [ accessed 2017 Jul 22]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000973/WC500054346.pdf.
- European Medicines Agency. Science medicines health. synflorix—procedural steps taken and scientific information after the authoristation. 2017 [ accessed 2018 Jan 8]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Procedural_steps_taken_and_scientific_information_after_authorisation/human/000973/WC500054350.pdf.
- Domingues CM, Verani JR, Montenegro Renoiner EI, De Cunto Brandileone C, Flannery B, De Oliveira LH, Barberino Santos J, Cassio De Moraes J. the Brazilian pneumococcal conjugate vaccine effectiveness study group. Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: a matched case-control study. Lancet Respir Med. 2014;2:464–471. doi: 10.1016/S2213-2600(14)70060-8.
- Synflorix Product Monograph, Canada. 2017 [ accessed 2017 Jul 22]. https://ca.gsk.com/media/591956/synflorix.pdf.
- Jokinen J, Rinta-Kokko H, Siira L, Palmu AA, Virtanen MJ, Nohynek H, Virolainen-Julkunen A, Toropainen M, Nuorti JP. Impact of ten-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in finnish children – a population-based study. PLoS One. 2015;10(3):e0120290. doi: 10.1371/journal.pone.0120290.
- Deceuninck G, De Serres G, Boulianne N, Lefebvre B, De Wals P. Effectiveness of three pneumococcal conjugate vaccines to prevent invasive pneumococcal disease in Quebec, Canada. Vaccine. 2015;33(23):2684–2689. doi: 10.1016/j.vaccine.2015.04.005.
- Haque A, Daniel S, Maxwell T, Boerstoel M. Postmarketing surveillance studies-an industry perspective on changing global requirements and implications. Clin Ther. 2017;39(4):675–685. doi: 10.1016/j.clinthera.2017.03.011.
- Ministry of Government Legislation. Postmarketing surveillance requirements (Articles 32 and 42) of the Pharmaceutical Affairs Act. 2017 [ accessed 2017 Dec 6]. http://www.moleg.go.kr/english/korLawEng;jsessionid=PXH070dZlpdewJk7Cul6Fs2Z51rMFKczqMCauKo2n4qHbxxhQhWjt6qPXpakh4TJ.moleg_a1_servlet_engine2?pstSeq=58356&pageIndex=3.
- Synflorix Prescribing Information for Korea. 2017 [ accessed 2017 Dec 6]. http://kr.gsk.com/ko-kr/%EC%A0%9C%ED%92%88%EC%A0%95%EB%B3%B4/%EB%B0%B1%EC%8B%A0/vaccines/%EC%8B%A0%ED%94%8C%EB%A1%9C%EB%A6%AD%EC%8A%A4-%ED%94%84%EB%A6%AC%ED%95%84%EB%93%9C%EC%8B%9C%EB%A6%B0%EC%A7%80/.
- Plosker GL. 10-Valent pneumococcal non-typeable haemophilus influenzae protein D-conjugate vaccine: a review in infants and children. Paediatr Drugs. 2014;16(5):425–444. doi: 10.1007/s40272-014-0089-x.
- Huu TN, Toan NT, Tuan HM, Viet HL, Le Thanh Binh P, Yu TW, Shafi F, Habib A, Borys D. Safety and reactogenicity of primary vaccination with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in Vietnamese infants: a randomised, controlled trial. BMC Infect Dis. 2013;13:95. doi: 10.1186/1471-2334-13-95.
- Omeñaca F, Merino JM, Tejedor JC, Constantopoulos A, Papaevangelou V, Kafetzis D, Tsirka A, Athanassiadou F, Anagnostakou M, François N, et al. Immunization of preterm infants with 10-valent pneumococcal conjugate vaccine. Pediatrics. 2011;128(2):e290–e298. doi: 10.1542/peds.2010-1184.
- Ministry of Food and Drug Safety. [Guideline for Re-examination of New Drugs]. 2012 [ accessed 2018 Jan 15]. http://www.mfds.go.kr/index.do?x=0&searchkey=title:contents&mid=1769&searchDivision=&searchClass=&searchword=%C0%E7%BD%C9%BB%E7&y=0&searchSubDivision=&pageNo=1&seq=12471&sitecode=2017-06-01&cmd=v.